AlphaMark Advisors LLC Sells 550 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

AlphaMark Advisors LLC reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 58.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 395 shares of the medical equipment provider’s stock after selling 550 shares during the period. AlphaMark Advisors LLC’s holdings in Zimmer Biomet were worth $42,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ZBH. First Bancorp Inc ME grew its holdings in Zimmer Biomet by 110.4% in the fourth quarter. First Bancorp Inc ME now owns 4,145 shares of the medical equipment provider’s stock worth $442,000 after purchasing an additional 2,175 shares during the period. Gradient Investments LLC increased its position in Zimmer Biomet by 5.5% in the 4th quarter. Gradient Investments LLC now owns 168,972 shares of the medical equipment provider’s stock valued at $17,849,000 after buying an additional 8,787 shares in the last quarter. CX Institutional boosted its holdings in Zimmer Biomet by 171.9% in the fourth quarter. CX Institutional now owns 2,336 shares of the medical equipment provider’s stock worth $247,000 after acquiring an additional 1,477 shares in the last quarter. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $204,000. Finally, Dakota Wealth Management increased its holdings in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $110.78 on Monday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The business’s 50 day simple moving average is $107.86 and its 200 day simple moving average is $108.13. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company has a market cap of $22.05 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company earned $1.65 EPS. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is currently 18.25%.

Analysts Set New Price Targets

Several research firms recently issued reports on ZBH. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Barclays dropped their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. BTIG Research decreased their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Finally, Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.